Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Jun. 2026, Prelude Therapeuticsspent$0.00 Mil on purchasing property, plant, equipment.
It gained$0.00 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$89.97 Mil on purchasing investments.
It gained$24.46 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it paid$0.00 Mil for other investing activities.
In all, Prelude Therapeuticsspent$65.50 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Jun. 2026.
Prelude Therapeutics's purchase of property, plant, equipment for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Prelude Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Prelude Therapeutics's sale of property, plant, equipment for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Prelude Therapeutics gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Prelude Therapeutics's purchase of business for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Prelude Therapeutics spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Prelude Therapeutics's sale of business for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Prelude Therapeutics gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Prelude Therapeutics's purchase of investment for the
three
months ended in Jun. 2026 was $-89.97 Mil. It means Prelude Therapeutics spent {stock_data.stock.currency_symbol}}89.97 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Prelude Therapeutics's sale of investment for the
three
months ended in Jun. 2026 was $24.46 Mil. It means Prelude Therapeutics gained $24.46 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Prelude Therapeutics's net Intangibles purchase and sale for the
three
months ended in Jun. 2026 was $0.00 Mil.
It means Prelude Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Prelude Therapeutics's cash from discontinued investing activities for the
three
months ended in Jun. 2026 was 0.00 Mil.
It means Prelude Therapeutics paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Prelude Therapeutics's cash from other investing activities for the
three
months ended in Jun. 2026 was $-0.00 Mil.
It means Prelude Therapeutics paid $0.00 Mil for other investing activities.
Prelude Therapeutics Cash Flow from Investing Related Terms
Prelude Therapeutics Cash Flow from Investing Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics Cash Flow from Investing Chart
Prelude Therapeutics Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Prelude Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-77.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Investing of $-77.25 Mil mean?
Prelude Therapeutics (PRLD) has a Cash Flow from Investing of $-77.25 Mil as of Jun. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Cash Flow from Investing too high?
Prelude Therapeutics' current Cash Flow from Investing is $-77.25 Mil. Overall, Prelude Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Cash Flow from Investing compare to CMPX and ARCT?
Prelude Therapeutics' Cash Flow from Investing of $-77.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Prelude Therapeutics and its competitors. Prelude Therapeutics's current Cash Flow from Investing is $-77.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Cash Flow from Investing of $-77.25 Mil. The current Cash Flow from Investing is $-77.25 Mil. Prelude Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Cash Flow from Investing is $-77.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
30GF Score
Get the complete analysis for PRLD
Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
